VR Logo

Cabaletta Bio Inc. (CABA) download report


Healthcare | Biotechnology & Pharma Research

Cabaletta Bio Inc. (CABA) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

IPO Date: 25-Oct-2019

Co-Founder, Chairman, CEO & Pres: Dr. Steven A. Nichtberger M.D.

Pres of Science & Technology: Dr. Gwendolyn K. Binder Ph.D.

Listing: NASDAQ: CABA

Country: United States

Headquarters: Philadelphia, PA

Website: https://www.cabalettabio.com

Key Facts

Market cap: $30.28 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-49.53 Mln

Cash: $109.21 Mln

Total Debt: $0.00 Mln

Insider's Holding: 4.31%

Liquidity: Low

52 Week range: $0.90 - 14.95

Shares outstanding: 28,977,100

5 Years Aggregate:

  • CFO: $-86.25 Mln
  • EBITDA: $-104.56 Mln
  • Net Profit: $-109.02 Mln

Stock Performance

Time Period Cabaletta Bio (CABA) S&P BSE Sensex S&P Small-Cap 600
YTD-72.03-9.18-18.78
1 month-20.30-4.78-8.00
3 months-47.78-9.66-13.65
1 Year-87.670.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Cabaletta Bio (CABA) S&P Small-Cap 600 S&P BSE Sensex
2021-69.6325.2721.99
2020-10.679.5715.75